313 related articles for article (PubMed ID: 10681722)
21. Applicability of international prognostic index in non Hodgkin's lymphoma in Pakistan.
Aziz Z; Sana S; Saeed S; Akram M
J Ayub Med Coll Abbottabad; 2004; 16(2):15-20. PubMed ID: 15455610
[TBL] [Abstract][Full Text] [Related]
22. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center.
Bouabdallah R; Coso D; Costello R; Bardou VJ; Blaise D; Xerri L; Sainty D; Maraninchi D; Gastaut JA
Bone Marrow Transplant; 2000 Jan; 25(1):35-40. PubMed ID: 10654012
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic significance of the histological classification and staging for patients with a malignant non-Hodgkin lymphoma].
Raemaekers JM; Snoeijen JJ; Bogman MJ; Rutten E; Strijk SP; Manni JJ
Ned Tijdschr Geneeskd; 1993 Apr; 137(16):815-20. PubMed ID: 8487885
[TBL] [Abstract][Full Text] [Related]
24. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
[TBL] [Abstract][Full Text] [Related]
25. [Non-Hodgkin's lymphomas. I. Clinico-biological features of 307 cases].
García Zueco JC; Delgado MP; Giraldo MP; Perella M; Torres M; Valero MI; Ríos MJ; García Julián G; Giralt M
Sangre (Barc); 1992 Oct; 37(5):331-6. PubMed ID: 1293771
[TBL] [Abstract][Full Text] [Related]
26. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
27. Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma.
Troch M; Wöhrer S; Raderer M
Anticancer Res; 2010 Feb; 30(2):635-9. PubMed ID: 20332482
[TBL] [Abstract][Full Text] [Related]
28. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
[TBL] [Abstract][Full Text] [Related]
29. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.
Mounier N; Morel P; Haioun C; Coiffier B; Tilly H; Chatelain C; Lederlin P; Thyss A; Herbrecht R; Gisselbrecht C; Lepage E
Cancer; 1998 May; 82(10):1952-62. PubMed ID: 9587130
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
[TBL] [Abstract][Full Text] [Related]
31. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
[TBL] [Abstract][Full Text] [Related]
32. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.
Lee J; Suh C; Park YH; Ko YH; Bang SM; Lee JH; Lee DH; Huh J; Oh SY; Kwon HC; Kim HJ; Lee SI; Kim JH; Park J; Oh SJ; Kim K; Jung C; Park K; Kim WS
J Clin Oncol; 2006 Feb; 24(4):612-8. PubMed ID: 16380410
[TBL] [Abstract][Full Text] [Related]
33. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O
Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938
[TBL] [Abstract][Full Text] [Related]
34. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
[TBL] [Abstract][Full Text] [Related]
35. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
36. Prognosis of localized diffuse large B-cell lymphoma in younger patients.
Møller MB; Christensen BE; Pedersen NT
Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468
[TBL] [Abstract][Full Text] [Related]
37. Prognostic relevance of non-Hodgkin's lymphomas cell cycle data.
Vucković J; Forenpoher G; Marusić M; UZarević B; Zemunik T
Neoplasma; 1998; 45(5):332-5. PubMed ID: 9921923
[TBL] [Abstract][Full Text] [Related]
38. Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.
Merli F; Bertini M; Luminari S; Mozzana R; Bertè R; Trottini M; Stelitano C; Botto B; Pizzuti M; Quintana G; De Paoli A; Federico M;
Haematologica; 2004 Aug; 89(8):973-8. PubMed ID: 15339681
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
40. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Ferrario A; Merli F; Luminari S; Stelitano C; Mannina D; Russo M; Mazza P; Marcheselli L; Goldaniga MC; Federico M; Baldini L;
Ann Hematol; 2011 Mar; 90(3):323-30. PubMed ID: 20848104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]